Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829.
Recent data suggest that somatostatin receptors (SSTRs) are expressed on various tumor cells. High-level expression of SSTR on the tumor cell surface provides the basis for the successful clinical use of radiolabeled ligands for the in vivo localization of tumor sites. We have characterized the in vitro binding properties of the novel SSTR ligand 99mTc-P829 using primary human tumors (carcinoids, breast cancers, intestinal adenocarcinomas, pheochromocytomas, small cell and non-small cell lung cancer, and melanomas; n = 28), various tumor cell lines, and COS7 cells transfected with the human SSTR (hSSTR) subtypes 1, 2, 3, 4, and 5. 99mTc-P829 bound to primary tumor cells and tumor cell lines with high affinity and high capacity. The dissociation constants (Kd) ranged between 1 and 20 nM. 99mTc-P829 also bound with high affinity to the transfected hSSTR2 (Kd, 2.5 nM), hSSTR5 (Kd, 2 nM), and hSSTR3 (Kd, 1.5 nM). Binding of 99mTc-P829 to hSSTR3 was found to be displaceable by unlabeled P829/([ReO]-P829), SST-14, and vasoactive intestinal peptide (VIP; IC50, 2 nM) and, less effectively, by Tyr3-octreotide (IC50, 20 nM). In contrast, the binding of 99mTc-P829 to hSSTR2 and hSSTR5 could be displaced by P829/([ReO]-P829) and Tyr3-octreotide but not by VIP. 99mTc-P829 scintigraphy revealed in vivo binding to primary or metastatic tumor sites in seven of eight patients with breast cancer and six of six patients with melanoma. In summary, our data show that 99mTc-P829 binds with high affinity to many different types of primary and cloned tumor cells. Furthermore, our data identify hSSTR2, the VIP acceptor hSSTR3, and hSSTR5 as the respective target receptors. Because these receptors are frequently expressed at high levels on primary tumor cells, 99mTc-P829 appears to be a promising novel peptide tracer for tumor imaging.
Virgolini
I
I
Department of Nuclear Medicine, University of Vienna, Austria. irene.virgolini@akh-wien.ac.at
Leimer
M
M
Handmaker
H
H
Lastoria
S
S
Bischof
C
C
Muto
P
P
Pangerl
T
T
Gludovacz
D
D
Peck-Radosavljevic
M
M
Lister-James
J
J
Hamilton
G
G
Kaserer
K
K
Valent
P
P
Dean
R
R
D000818:Animals; D001667:Binding, Competitive; D015152:Blotting, Northern; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism; D019556:COS Cells / Q000378:metabolism; D005260:Female; D006801:Humans; D008545:Melanoma / Q000000981:diagnostic imaging / Q000378:metabolism; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism*; D010456:Peptides, Cyclic / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis; D011869:Radioligand Assay; D017481:Receptors, Somatostatin / Q000235:genetics / Q000378:metabolism*; D012680:Sensitivity and Specificity; D013670:Sodium Pertechnetate Tc 99m / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon; D014407:Tumor Cells, Cultured / Q000378:metabolism
D010456:Peptides, Cyclic; D012333:RNA, Messenger; D017481:Receptors, Somatostatin; D013670:Sodium Pertechnetate Tc 99m; C100464:P 829